Electromedical Technologies (OTCMKTS:EMED) Stock Sees High Volatility: here is Why

Pioneer in the development and production of bioelectronics devices designed for relieving chronic and acute pains, Electromedical Technologies (OTCMKTS:EMED) on July 29, 2021, announced the expansion of its Stage I research programs collaborating with Nazarbayev University for developing an Alzheimer’s disease therapy.

The unique research program can lead to non-invasive bioelectronic therapy development as an alternative for pharmaceutical therapy. Reports suggest that 44 million people globally suffer from Alzheimer’s Disease or dementia. Alzheimer’s Disease treatment will reach $13.3 billion in 2023, according to GlobalData.

Matthew Wolfson, Founder, and CEO of Electromedical Technologies said that exploration of alternative therapies must be done for future generations. Wolfson said that the company is expanding programs and is a significant focus of its research team led by Professor Dos D. Sarbassov, Professor of the Department of Biology, School of Sciences and Humanities at Nazarbayev University.

Dr. Dos Sarbassovsaid that it is a collaborative effort of academic institutions together with the industrial sector that will be important for advancing the development of a potent neuroprotective therapy for alleviating AD-related brain pathology.

Dr.SholpanAskarova said that monitoring oxidative stress in astrocytic and neuronal cells is the working platform for identifying potent electrical frequencies to neutralize the damage.

Wolfson further said the company’s flagship device, the Wellness Pro Plus, has been facilitating pain-free life for thousands of people. He added that the research is exciting on the possibilities and will provide a solid foundation in the development of effective novel therapies.